Advanced stage gastric cancer and neoadjuvant chemotherapy Our experience in surgical resectability
Main Article Content
Abstract
BACKGROUND: In the last years the incidence of gastric cancer is changed as the complementary therapy to surgical treatment especially about the advanced stage gastric cancer.
MATERIALS AND METHODS: We have analyzed the patients treated at Unit of General Surgery and Organ Transplantation of University Hospital of Parma from 1/1/2009 to 30/9/2012. The cases surgically treated after neoadiuvant therapy were compared to patients not treated with neoadiuvant therapy.The choice to neoadiuvant therapy was decided on locally advanced disease and low comorbidity.
RESULTS: The cases surgically treated were 93, in 9 cases were treated with neoadiuvant therapy. The histotype in neoadiuvant cases was an intestinale type 3 cases, a diffuse type 3 cases and no classificable sec. Lauren 3 cases. The average of number of lymphnodes removed was 22.5 in total gastrectomy and 15.7 nodes in partial gastrectomy. On RECIST criteria the response to neoadiuvant chemotherapy were in 2 cases a partial response and in the others 7 cases the disease remained stable.
CONCLUSION: In our experience as in literature, the neoadiuvant therapy can reduce staging, increases the R0 resection, should proposed in young patients with low comorbidity.